FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * Young Richard A			2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]				:	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2020					Office	r (give title belo	ow)	Other (specify be	elow)		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				-	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
	CAMBRIDGE, MA 02140 (City) (State) (Zip)			Table I - Non-Derivative Securities Acou					Acqui	ured, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i	3. Transaction Code (Instr. 8)		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)		quired of (D)	5. Amoun Beneficia Reported	nt of Securities ally Owned Following Transaction(s)		6. Ownership Form:	Beneficial
				(Month/Day/Year	Code	V	Amoun	(A) or (D)	(Instr. 3 and 4)		nd 4)	d 4)		Ownership (Instr. 4)
Common Stock 06/3		06/15/2020		S ⁽¹⁾	4	5,990	111	\$ 8.75	359,161		D	D		
Reminder:	Report on a s	separate line for	each class of secur	ities beneficially o	wned direc	Pers cont	ons wh	no respo n this fo	rm are	not requ		spond unle	ss	1474 (9-02)
Reminder:	Report on a s	separate line for	Table II - l	Derivative Securi	ies Acqui	Pers cont the f	ons what ained in the constant of the constant	no respo n this fo splays a	rm are currer reficiall	not requ itly valid	uired to res		ss	1474 (9-02)
1. Title of		3. Transaction Date (Month/Day/Y	Table II - 1 (3A. Deemed Execution Da	Derivative Securites, valls, w	ies Acquii arrants, o	Pers cont the f	ons what ained in the constant of the constant	no respo n this fo splays a of, or Ber tible secu cisable on Date	rm are currer reficiall rities) 7. Tir Amo Unde Secu	not requitly valid y Owned tle and unt of erlying	OMB conf	spond unle	of 10. Ownersh Form of Derivatin Security Direct (I or Indire	11. Nature of Indirection of Indirec

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	X				

Signatures

/s/ Gerald E. Quirk, as attorney in fact	06/16/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.